查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677291

性行為感染診斷市場按疾病類型、檢測類型、樣本類型、最終用戶和分銷管道分類 - 2025 年至 2030 年全球預測

Sexually Transmitted Diseases Diagnostics Market by Disease Type, Test Types, Sample Type, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

性行為感染診斷市場預計到 2024 年將達到 127.8 億美元，到 2025 年將達到 135.3 億美元，到 2030 年將達到 181.7 億美元，複合年成長率為 6.03%。

主要市場統計數據
基準年 2024 年 127.8億美元
預計 2025 年 135.3億美元
預測年份 2030 181.7億美元
複合年成長率（%） 6.03%

在性行為感染傳染病 (STD) 診斷這一動態領域，不斷的技術創新和不斷發展的醫療實踐正在重塑疾病的檢測和管理方式。隨著全球性傳染病負擔不斷增加，對快速、準確且易於取得的診斷解決方案的需求從未如此強烈。現代診斷技術不僅提高了準確性，而且大大減少了檢測時間，為早期治療和預防鋪平了道路。這份全面的摘要詳細概述了影響市場的關鍵促進因素，提供了對細分和區域表現的見解，並強調了在該關鍵領域營運的公司的戰略方向。

當前階段的技術進步和綜合診斷程序正在改變傳統的醫療實踐。從實驗室專業人員和臨床醫生到公共衛生策略家，相關人員都受益於精準和快速反應的時代。正如我們將在以下章節中討論的那樣，診斷領域正在經歷重大變革時期，這將影響市場動態和患者照護。本報告透過最新資料和趨勢闡明了這些轉變，這對於試圖駕馭臨床需求和技術創新之間複雜相互作用的決策者至關重要。

改變性行為感染診斷市場

近年來，變革性的技術、監管和市場變化重新定義了性傳染感染診斷產業。分子生物學和數位分析的進步促進了照護現場和實驗室檢測方法的快速改進。這些創新提高了診斷的準確性，縮短了檢測時間，並使不同患者群體更容易接受檢測。同時，法律規範和報銷政策的變化為市場參與企業創造了新的機會，同時迫使現有企業重新調整產品系列。

核酸擴增技術和快速血漿再評估檢測等新技術現已成為下一代診斷技術的支柱。這些技術，加上與用於資料解釋和遠端監控的數位系統的日益整合，使臨床醫生能夠做出更明智的決策。這種演變不僅限於臨床應用，還延伸到了市場動態，轉向針對患者概況和本地醫療保健基礎設施量身定做的個人化診斷解決方案。隨著競爭格局適應這些新趨勢，相關人員被鼓勵不斷創新，確保服務交付的速度與診斷能力的快速進步相符。

深入了解性傳染感染診斷的關鍵環節

市場區隔的詳細分析可以讓我們清楚了解 STI 診斷生態系統的各個方面。它根據疾病類型對市場進行剖析，檢查主要病原體，包括披衣菌感染、淋病、單純皰疹病毒 (HSV)、人類免疫力缺乏病毒 (HIV)、人類乳突病毒 (HPV) 和梅毒。這種詳細的分類揭示了集體爆發發生率、人口影響和地理流行的清晰模式。關於測試類型的調查主要集中於實驗室測試與就地檢驗。實驗室檢測已被廣泛研究，包括酵素結合免疫吸附檢測法(ELISA)、核酸增幅檢查(NAAT) 和快速血漿反應檢測 (RPR) 等成熟技術，而就地檢驗包括家庭檢測套組和快速檢測等工具。基於樣本類型的研究檢查了血液、尿液和陰道拭子的診斷效用，強調了與每種樣本相關的不同敏感性和特異性。細分繼續透過分析最終用戶概況來進行，範圍包括居家醫療、醫院/診所、照護端、公共衛生實驗室和研究實驗室。最後，我們進一步按分銷管道細分市場，比較直銷與代理商網路，以確定市場滲透率和服務交付效率。這種細緻的細分研究突顯了每個細分市場獨特的複雜性和不同需求，從而影響診斷策略和投資。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球性行為感染傳染病的發生率和認知度不斷上升
      • 政府和衛生組織加強支持政策和措施的實施力度
      • 它將擴大醫療保健服務的覆蓋率，並提高全球性行為感染診斷服務的可用性和利用率。
    • 限制因素
      • 與診斷檢測是否能夠跟上不斷演化的菌株和新病原體有關的問題
    • 機會
      • 透過診斷公司和醫療保健提供者或非政府組織之間的合作實現成長的潛力
      • 創新就地檢驗，減少對專業實驗室和醫護人員的需求
    • 任務
      • 與跨多個地區的複雜法規環境相關的擔憂
  • 市場區隔分析
    • 疾病類型：披衣菌感染核酸增幅檢查具有高度敏感性和特異性，因此越來越有必要。
    • 最終用戶：醫院和診所性行為感染診斷的應用將迅速增加，從而實現準確、及時的診斷。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會的
    • 技術的
    • 合法的
    • 環境

第6章性行為感染傳染病診斷市場（依疾病類型）

  • 披衣菌感染
  • 淋病
  • 單純皰疹病毒 (HSV)
  • 人類免疫力缺乏病毒（HIV）
  • 人類乳突病毒 (HPV)
  • 梅毒

第 7 章性行為感染傳染病診斷市場（按測試類型）

  • 實驗室測試
    • 酵素免疫分析法（ELISA）
    • 核酸增幅檢查（NAAT）
    • 快速血漿反應素 (RPR)
  • 就地檢驗
    • 家庭檢測套組
    • 快速檢測

第 8 章性行為感染傳染病診斷市場（依樣本類型）

  • 血
  • 尿
  • 陰道拭子

第 9 章性行為感染傳染病診斷市場（依最終用戶）

  • 家庭護理設置
  • 醫院和診所
  • 照護現場設置
  • 公共衛生研究所
  • 研究部門

第 10 章性行為感染傳染病診斷市場（依通路）

  • 直接銷售
  • 經銷商

11.美洲性行為感染傳染病診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區性行為感染傳染病診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲性行為感染傳染病診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Abbott Laboratories
  • Astra Biotech GmbH
  • Becton Dickinson and company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • Daye Limited
  • Diasorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Geneproof
  • Hologic Inc.
  • Jiangsu BioPerfectus Technologies Co., Ltd
  • Liferiver Bio-Tech Corp.
  • MedMira Inc.
  • Merck KGaA
  • Meridian Bioscience Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Qiagen Inc.
  • Quest Consumer Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-5319A8C1C5A6

The Sexually Transmitted Diseases Diagnostics Market was valued at USD 12.78 billion in 2024 and is projected to grow to USD 13.53 billion in 2025, with a CAGR of 6.03%, reaching USD 18.17 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 12.78 billion
Estimated Year [2025] USD 13.53 billion
Forecast Year [2030] USD 18.17 billion
CAGR (%) 6.03%

In the dynamic field of sexually transmitted diseases (STDs) diagnostics, constant innovation and evolving healthcare practices are reshaping how diseases are detected and managed. As the global burden of STDs continues to rise, the need for prompt, accurate, and accessible diagnostic solutions has never been more critical. Modern diagnostic technologies are not only improving accuracy but are also drastically reducing turnaround times, paving the way for early treatment and prevention. This comprehensive summary provides an in-depth overview of the key drivers influencing the market, offers insights into segmentation and regional performance, and highlights strategic directions for companies engaged in this critical space.

The current stage of integration between technological advancements and diagnostic procedures is transforming traditional practices. Stakeholders, ranging from laboratory professionals and clinicians to public health strategists, are benefiting from an era marked by precision and rapid response. As we explore in subsequent sections, the diagnostic landscape is undergoing significant transformative shifts that influence market dynamics and patient care. This report sheds light on these shifts, drawing on recent data and trends essential for decision-makers looking to navigate the complex interplay between clinical needs and technological innovations.

Transformative Shifts in the STI Diagnostics Industry Landscape

Over recent years, transformative shifts across technological, regulatory, and market dimensions have redefined the STI diagnostics industry. Advances in molecular biology and digital analytics have led to rapid enhancements in point-of-care and laboratory testing modalities. These innovations have bolstered diagnostic accuracy, reduced testing timeframes, and made testing more accessible to diverse patient populations. In parallel, changes in regulatory frameworks and reimbursement policies have opened up new opportunities for market entrants, while prompting established companies to recalibrate their product portfolios.

Emerging technologies such as nucleic acid amplification techniques and rapid plasma reevaluation assays now serve as the backbone for next-generation diagnostics. These technologies, coupled with the increasing integration of digital systems for data interpretation and remote monitoring, are enabling clinicians to make more informed decisions. This evolution is not limited to clinical application alone; it extends to market dynamics as well, with an observable shift towards personalized diagnostic solutions that are tailored to both patient demographics and regional healthcare infrastructures. As competitive landscapes adjust to these emerging trends, stakeholders are urged to innovate continuously, ensuring that the pace of service delivery matches the rapid advances in diagnostic capabilities.

Key Segmentation Insights in STI Diagnostics

A detailed analysis of market segmentation provides a clear understanding of the diverse dimensions characterizing the STI diagnostics ecosystem. The market is dissected based on disease type, examining key pathogens including Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), and Syphilis. This detailed categorization reveals distinct patterns in outbreak incidences, demographic impacts, and regional prevalence. In our investigation of test types, the focus is on the contrast between laboratory testing and point-of-care testing. Laboratory testing is extensively researched through established techniques such as Enzyme-linked Immunosorbent Assays (ELISA), Nucleic Acid Amplification Tests (NAATs), and Rapid Plasma Reagin (RPR), while point-of-care testing encompasses tools including home testing kits and rapid tests. An exploration based on sample type looks into the diagnostic utility of blood, urine, and vaginal swabs, highlighting different sensitivities and specificities pertinent to each sample. The segmentation continues with an analysis on end-user profiles, ranging from homecare settings, hospitals and clinics, and point-of-care settings to public health labs and research laboratories. Finally, the market is further segmented by distribution channel, comparing direct sales with distributor networks to elucidate market penetration and service delivery efficiencies. These nuanced segmentation studies underline the complexity and tailored needs inherent to each market segment, influencing diagnostic strategies and investments.

Based on Disease Type, market is studied across Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), and Syphilis.

Based on Test Types, market is studied across Laboratory Testing and Point-of-Care Testing. The Laboratory Testing is further studied across Enzyme-linked Immunosorbent Assay (ELISA), Nucleic Acid Amplification Tests (NAATs), and Rapid Plasma Reagin (RPR). The Point-of-Care Testing is further studied across Home Testing Kits and Rapid Tests.

Based on Sample Type, market is studied across Blood, Urine, and Vaginal Swabs.

Based on End-User, market is studied across Homecare Settings, Hospitals & Clinics, Point-of-Care Settings, Public Health Labs, and Research Laboratories.

Based on Distribution Channel, market is studied across Direct Sales and Distributors.

Regional Dynamics Shaping the STI Diagnostics Market

The global STI diagnostics market exhibits varied growth trajectories influenced by regional healthcare frameworks and economic priorities. The Americas are witnessing rapid adoption of advanced diagnostic tools driven by an increasing emphasis on early detection and preventive care. In addition, regulatory support and robust healthcare infrastructure are accelerating the integration of innovative testing methodologies, making the region one of the most dynamic in the current landscape. Europe, the Middle East, and Africa collectively present a diverse set of challenges and opportunities. European markets lead in regulatory compliance and technological advancements, while the Middle East and Africa provide emerging markets with significant unmet diagnostic needs. Each of these regions is responding to local challenges by adopting scalable diagnostic solutions that resonate with public health strategies. The Asia-Pacific region, characterized by rapid economic growth and a burgeoning population, is increasingly focusing on the implementation of cost-effective and accessible diagnostic platforms. Region-specific trends, workforce capabilities, and healthcare investments are all influencing the manner in which diagnostics evolve to meet distinct regional requirements. Together, these regional insights offer a comprehensive view of the disparate yet interconnected elements that drive market innovation and expansion on a worldwide scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies and Their Impact on Diagnostic Innovations

The STI diagnostics market landscape is highly competitive, with several prominent companies driving technological advancements and market growth. Industry leaders such as Abbott Laboratories, Astra Biotech GmbH, Becton Dickinson and company, Bio-Rad Laboratories, Inc., and bioMerieux SA are at the forefront of innovation, developing robust tools and platforms that redefine diagnostic accuracy. In addition, powerhouses like Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd., and Geneproof continue to build upon rich legacies in diagnostic research and clinical application. The influence of companies such as Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., and MedMira Inc. is reflected in their rapid adoption of state-of-the-art diagnostic technologies, contributing to enhanced patient outcomes across multiple regions. Furthermore, distinguished names like Merck KGaA, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., Novartis AG, OraSure Technologies, Inc., Qiagen Inc., Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. are emblematic of the drive toward innovation and comprehensive disease management. These companies are continuously pushing the boundaries of diagnostic science, with ongoing investments in research and development fostering an ecosystem that supports both rapid technological innovations and strategic collaborations across the healthcare network.

The report delves into recent significant developments in the Sexually Transmitted Diseases Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech GmbH, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd., Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc., Merck KGaA, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., Novartis AG, OraSure Technologies, Inc., Qiagen Inc., Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.. Strategic Recommendations for Industry Leaders in STI Diagnostics

In light of the critical shifts and segmentation complexities inherent in the STI diagnostics market, industry leaders are encouraged to adopt a series of actionable strategies. Foremost, it is imperative that companies invest in the advancement of both molecular diagnostic technologies and digital analytic platforms that not only enhance operational efficiency but also ensure timely and precise results. This involves a reallocation of resources towards research and development, with a focus on emerging technologies that have demonstrated potential in enhancing sensitivity and specificity. In parallel, firms should consider strategic collaborations with regulatory bodies and academic institutions to streamline the translation of innovative diagnostic technologies into market-ready solutions. Capitalizing on regional strengths and diversifying distribution strategies is essential, particularly by leveraging the heterogeneous needs of diverse customer segments identified through the segmentation studies. Enhancing communication channels with end-user groups such as hospitals, public health labs, and homecare settings will further ensure that the developed diagnostic tools meet practical clinical needs. Additionally, a measured expansion into emerging markets, supported by localized product adaptations and pricing strategies, will drive sustainable growth. A cohesive strategy merging technological innovation with effective market penetration and strategic partnerships is likely to secure a competitive edge in this rapidly evolving field.

Synthesis and Conclusive Insights on STI Diagnostics

In summary, the landscape of sexually transmitted diseases diagnostics is undergoing transformative changes powered by technological breakthroughs, evolving regulatory frameworks, and an increased emphasis on precision medicine. The analysis provided in this report uncovers multifaceted segmentation across disease types, test modalities, sample types, end-user classifications, and distribution channels - all of which contribute to a comprehensive understanding of market dynamics and strategic opportunities. Regional insights highlight significant discrepancies in market maturity and adoption rates, while leading companies continuously push the envelope in both innovation and application. The integration of state-of-the-art diagnostic techniques with effective market strategies is paving the way for improved patient outcomes and enhanced public health responses. This synthesis bridges the gap between clinical innovation and market trends, urging stakeholders to focus on sustained investment in evolving technologies and strategic partnerships. Thus, the confluence of these factors not only solidifies the current market status but also paves the way for future advancements in the detection and management of sexually transmitted diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and awareness of STDs globally
      • 5.1.1.2. Growing implementation of supportive policies and initiatives from governments and health organizations
      • 5.1.1.3. Expanded access to healthcare services facilitates greater availability and use of STD diagnostic services across globe
    • 5.1.2. Restraints
      • 5.1.2.1. Issues related to ability to keep diagnostic tests up-to-date with evolving strains and emerging pathogens
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing potential with partnerships between diagnostic companies and healthcare providers or NGOs
      • 5.1.3.2. Innovations in point-of-care testing to reduce the need for specialized laboratories and healthcare personnel
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with complex regulatory environments across different regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Increasing need for nucleic acid amplification tests in chlamydia owing to high sensitivity and specificity
    • 5.2.2. End-User: Proliferating applications of STD diagnostics in hospitals and clinics for accurate and timely diagnosis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sexually Transmitted Diseases Diagnostics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Chlamydia
  • 6.3. Gonorrhea
  • 6.4. Herpes Simplex Virus (HSV)
  • 6.5. Human Immunodeficiency Virus (HIV)
  • 6.6. Human Papillomavirus (HPV)
  • 6.7. Syphilis

7. Sexually Transmitted Diseases Diagnostics Market, by Test Types

  • 7.1. Introduction
  • 7.2. Laboratory Testing
    • 7.2.1. Enzyme-linked Immunosorbent Assay (ELISA)
    • 7.2.2. Nucleic Acid Amplification Tests (NAATs)
    • 7.2.3. Rapid Plasma Reagin (RPR)
  • 7.3. Point-of-Care Testing
    • 7.3.1. Home Testing Kits
    • 7.3.2. Rapid Tests

8. Sexually Transmitted Diseases Diagnostics Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Blood
  • 8.3. Urine
  • 8.4. Vaginal Swabs

9. Sexually Transmitted Diseases Diagnostics Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals & Clinics
  • 9.4. Point-of-Care Settings
  • 9.5. Public Health Labs
  • 9.6. Research Laboratories

10. Sexually Transmitted Diseases Diagnostics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Direct Sales
  • 10.3. Distributors

11. Americas Sexually Transmitted Diseases Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Sexually Transmitted Diseases Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Sexually Transmitted Diseases Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Labcorp and NOWDiagnostics collaborate to expand rapid syphilis testing amid rising STI cases nationwide
    • 14.3.2. Sherlock Biosciences innovative clinical trial for rapid OTC STI diagnostics
    • 14.3.3. Binx Health secures USD 65 million to enhance rapid point-of-care STI diagnostics
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astra Biotech GmbH
  • 3. Becton Dickinson and company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Danaher Corporation
  • 7. Daye Limited
  • 8. Diasorin S.p.A
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. Geneproof
  • 11. Hologic Inc.
  • 12. Jiangsu BioPerfectus Technologies Co., Ltd
  • 13. Liferiver Bio-Tech Corp.
  • 14. MedMira Inc.
  • 15. Merck KGaA
  • 16. Meridian Bioscience Inc.
  • 17. Mylab Discovery Solutions Pvt. Ltd.
  • 18. Novartis AG
  • 19. OraSure Technologies, Inc.
  • 20. Qiagen Inc.
  • 21. Quest Consumer Inc.
  • 22. Sansure Biotech Inc.
  • 23. Seegene Inc.
  • 24. Siemens Healthineers AG
  • 25. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-CURRENCY
  • FIGURE 2. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 4. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID PLASMA REAGIN (RPR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOME TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY VAGINAL SWABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2